BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-4.06M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.39× | Operating cash flow / net income. Period ending 2026-06-30. $-4.06M ÷ $-10.52M ≈ 0.39× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -4.06M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -10.52M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-4.06M | (m) | (m) | (m) | (m) | $-10.52M | (m) | (m) | (m) | 0.39× |
| 2026-03-31 | (m) | (m) | $-6.66M | (m) | (m) | (m) | (m) | $-9.57M | (m) | (m) | (m) | 0.70× |
| 2025-12-31 | (m) | (m) | $-6.97M | (m) | (m) | (m) | (m) | $-10.31M | (m) | (m) | (m) | 0.68× |
| 2025-09-30 | (m) | (m) | $-7.28M | (m) | (m) | (m) | (m) | $-10.85M | (m) | (m) | (m) | 0.67× |
| 2025-06-30 | (m) | (m) | $-9.48M | (m) | (m) | (m) | (m) | $-11.45M | (m) | (m) | (m) | 0.83× |
| 2025-03-31 | (m) | (m) | $-7.66M | (m) | (m) | (m) | (m) | $-11.09M | (m) | (m) | (m) | 0.69× |
| 2024-12-31 | (m) | (m) | $-9.09M | (m) | (m) | (m) | (m) | $-11.62M | (m) | (m) | (m) | 0.78× |
| 2024-09-30 | (m) | (m) | $-11.33M | (m) | (m) | (m) | (m) | $-14.23M | (m) | (m) | (m) | 0.80× |
| 2024-06-30 | (m) | (m) | $-14.44M | (m) | (m) | (m) | (m) | $-12.75M | (m) | (m) | (m) | 1.13× |
| 2024-03-31 | (m) | (m) | $-19.54M | (m) | (m) | (m) | (m) | $-15.53M | (m) | (m) | (m) | 1.26× |
| 2023-12-31 | $-20.48M | (m) | $-20.46M | $18.00K | (m) | (m) | (m) | $-17.19M | (m) | (m) | (m) | 1.19× |
| 2023-09-30 | $-21.84M | (m) | $-21.82M | $18.00K | (m) | (m) | (m) | $-16.63M | (m) | (m) | (m) | 1.31× |
| 2023-06-30 | (m) | (m) | $-20.26M | (m) | (m) | (m) | (m) | $-22.26M | (m) | (m) | (m) | 0.91× |
| 2023-03-31 | (m) | (m) | $-19.62M | (m) | (m) | (m) | (m) | $-23.98M | (m) | (m) | (m) | 0.82× |
| 2022-12-31 | $-19.35M | (m) | $-19.32M | $29.00K | (m) | (m) | (m) | $-24.28M | (m) | (m) | (m) | 0.80× |
| 2022-09-30 | $-20.24M | (m) | $-20.18M | $64.00K | (m) | (m) | (m) | $-25.45M | (m) | (m) | (m) | 0.79× |
| 2022-06-30 | $-22.09M | (m) | $-21.79M | $300.00K | (m) | (m) | (m) | $-23.93M | (m) | (m) | (m) | 0.91× |
| 2022-03-31 | $-21.29M | (m) | $-20.98M | $309.00K | (m) | (m) | (m) | $-23.16M | (m) | (m) | (m) | 0.91× |
| 2021-12-31 | $-26.59M | (m) | $-26.27M | $330.00K | (m) | (m) | (m) | $-24.46M | (m) | (m) | (m) | 1.07× |
| 2021-09-30 | $-28.86M | (m) | $-28.34M | $528.00K | (m) | (m) | (m) | $-30.08M | (m) | (m) | (m) | 0.94× |
| 2021-06-30 | $-29.18M | (m) | $-28.80M | $379.00K | (m) | (m) | (m) | $-29.23M | (m) | (m) | (m) | 0.99× |
| 2021-03-31 | $-29.53M | (m) | $-29.13M | $401.00K | (m) | (m) | (m) | $-30.36M | (m) | (m) | (m) | 0.96× |
| 2020-12-31 | $-35.57M | (m) | $-35.19M | $378.00K | (m) | (m) | (m) | $-31.81M | (m) | (m) | (m) | 1.11× |
| 2020-09-30 | $-31.38M | (m) | $-30.89M | $491.00K | (m) | (m) | (m) | $-27.69M | (m) | (m) | (m) | 1.12× |
| 2020-06-30 | $-28.10M | (m) | $-27.59M | $505.00K | (m) | (m) | (m) | $-28.83M | (m) | (m) | (m) | 0.96× |
| 2020-03-31 | $-25.92M | (m) | $-25.44M | $476.00K | (m) | (m) | (m) | $-26.34M | (m) | (m) | (m) | 0.97× |
| 2019-12-31 | $-11.72M | (m) | $-11.25M | $473.00K | (m) | (m) | (m) | $-23.25M | (m) | (m) | (m) | 0.48× |
| 2019-09-30 | $-11.93M | (m) | $-11.69M | $235.00K | (m) | (m) | (m) | $-20.94M | (m) | (m) | (m) | 0.56× |
| 2019-06-30 | $-14.79M | (m) | $-14.66M | $134.00K | (m) | (m) | (m) | $-18.49M | (m) | (m) | (m) | 0.79× |
| 2019-03-31 | $-11.43M | (m) | $-11.10M | $328.00K | (m) | (m) | (m) | $-16.68M | (m) | (m) | (m) | 0.67× |
| 2018-12-31 | $-12.76M | (m) | $-12.39M | $369.00K | (m) | (m) | (m) | $-13.95M | (m) | (m) | (m) | 0.89× |
| 2018-09-30 | $-11.92M | (m) | $-11.60M | $323.00K | (m) | (m) | (m) | $-8.29M | (m) | (m) | (m) | 1.40× |
| 2018-06-30 | $-1.57M | (m) | $-1.16M | $408.00K | (m) | (m) | (m) | $-7.52M | (m) | (m) | (m) | 0.15× |
| 2018-03-31 | $-3.07M | (m) | $-2.85M | $225.00K | (m) | (m) | (m) | $-5.46M | (m) | (m) | (m) | 0.52× |
| 2017-12-31 | $-2.54M | (m) | $-2.36M | $180.00K | (m) | (m) | (m) | $-4.95M | (m) | (m) | (m) | 0.48× |
| 2017-09-30 | $-750.00K | (m) | $-625.00K | $125.00K | (m) | (m) | (m) | $-5.85M | (m) | (m) | (m) | 0.11× |
| 2017-06-30 | $-4.79M | (m) | $-4.74M | $50.00K | (m) | (m) | (m) | $-5.05M | (m) | (m) | (m) | 0.94× |
| 2017-03-31 | $-4.60M | (m) | $-4.52M | $77.00K | (m) | (m) | (m) | $-4.98M | (m) | (m) | (m) | 0.91× |
| 2016-12-31 | $-5.96M | (m) | $-5.86M | $103.00K | (m) | (m) | (m) | $-4.98M | (m) | (m) | (m) | 1.18× |
| 2016-09-30 | $-6.07M | (m) | $-5.95M | $113.00K | (m) | (m) | (m) | $-5.74M | (m) | (m) | (m) | 1.04× |
| 2016-06-30 | $-8.32M | (m) | $-8.21M | $114.00K | (m) | (m) | (m) | $-6.74M | (m) | (m) | (m) | 1.22× |
| 2016-03-31 | $-8.52M | (m) | $-8.45M | $71.00K | (m) | (m) | (m) | $-8.04M | (m) | (m) | (m) | 1.05× |
| 2015-12-31 | $-7.45M | (m) | $-7.41M | $45.00K | (m) | (m) | (m) | $-8.49M | (m) | (m) | (m) | 0.87× |
| 2015-09-30 | $-8.22M | (m) | $-8.12M | $95.00K | (m) | (m) | (m) | $-9.83M | (m) | (m) | (m) | 0.83× |
| 2015-06-30 | $-6.80M | (m) | $-6.71M | $83.00K | (m) | (m) | (m) | $-9.65M | (m) | (m) | (m) | 0.70× |
| 2015-03-31 | $-6.10M | (m) | $-6.03M | $67.00K | (m) | (m) | (m) | $-9.37M | (m) | (m) | (m) | 0.64× |
| 2014-12-31 | $-4.65M | (m) | $-4.49M | $161.00K | (m) | (m) | (m) | $-9.25M | (m) | (m) | (m) | 0.49× |
| 2014-09-30 | $-4.19M | (m) | $-4.09M | $105.00K | (m) | (m) | (m) | $-7.73M | (m) | (m) | (m) | 0.53× |
| 2014-06-30 | $-3.82M | (m) | $-3.68M | $136.00K | (m) | (m) | (m) | $-6.39M | (m) | (m) | (m) | 0.58× |
| 2014-03-31 | $-3.96M | (m) | $-3.77M | $182.00K | (m) | (m) | (m) | $-5.93M | (m) | (m) | (m) | 0.64× |
| 2013-12-31 | $-4.16M | (m) | $-4.05M | $108.00K | (m) | (m) | (m) | $-4.90M | (m) | (m) | (m) | 0.83× |
| 2013-09-30 | $-3.23M | (m) | $-3.12M | $112.00K | (m) | (m) | (m) | $-4.26M | (m) | (m) | (m) | 0.73× |
| 2013-06-30 | $-3.58M | (m) | $-3.48M | $95.00K | (m) | (m) | (m) | $-4.33M | (m) | (m) | (m) | 0.80× |
| 2013-03-31 | $-2.90M | (m) | $-2.84M | $58.00K | (m) | (m) | (m) | $-3.64M | (m) | (m) | (m) | 0.78× |
| 2012-12-31 | $-3.01M | (m) | $-2.92M | $90.00K | (m) | (m) | (m) | $-3.43M | (m) | (m) | (m) | 0.85× |
| 2012-09-30 | $-2.79M | (m) | $-2.71M | $85.00K | (m) | (m) | (m) | $-4.27M | (m) | (m) | (m) | 0.63× |
| 2012-06-30 | $-2.60M | (m) | $-2.53M | $72.00K | (m) | (m) | (m) | $-4.02M | (m) | (m) | (m) | 0.63× |
| 2012-03-31 | $-2.98M | (m) | $-2.91M | $63.00K | (m) | (m) | (m) | $-4.08M | (m) | (m) | (m) | 0.71× |
| 2011-12-31 | $-2.27M | (m) | $-2.22M | $48.00K | (m) | (m) | (m) | $-3.92M | (m) | (m) | (m) | 0.57× |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-1.86M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-1.85M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-2.07M | (m) | $-2.07M | $5.00K | (m) | (m) | (m) | $-2.42M | (m) | (m) | (m) | 0.86× |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |